{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:59:19Z","timestamp":1787241559918,"version":"build-2736575974"},"reference-count":110,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>In the past decades, percutaneous coronary intervention (PCI) has become the most common modality for myocardial revascularization in patients with coronary artery disease (CAD). Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is essential in all patients undergoing PCI to prevent thrombotic complications. A large proportion of patients undergoing PCI also have concomitant atrial fibrillation (AF), thus requiring an oral anticoagulant (OAC) to prevent ischemic stroke or systemic embolism. However, the association between OAC and DAPT further increases the risk of bleeding. Compared with a triple antithrombotic therapy (TAT), dual antithrombotic therapy (DAT) has shown to reduce bleeding events, but at the cost of higher risk of stent thrombosis. In this field, patients with AF undergoing PCI represent a special population with significant challenges, and several strategies are needed to reduce the risk for bleeding complications. In this review, we will discuss both the procedural and antithrombotic strategies to optimize ischemic and bleeding outcomes in patients with AF undergoing PCI.<\/jats:p>","DOI":"10.3390\/jcdd12040142","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T11:05:02Z","timestamp":1744110302000},"page":"142","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Procedural and Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Narrative Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-910X","authenticated-orcid":false,"given":"Domenico Simone","family":"Castiello","sequence":"first","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Buongiorno","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Manzi","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-823X","authenticated-orcid":false,"given":"Viviana","family":"Narciso","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imma","family":"Forzano","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Florimonte","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Sperandeo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8452-7464","authenticated-orcid":false,"given":"Mario Enrico","family":"Canonico","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-7888","authenticated-orcid":false,"given":"Marisa","family":"Avvedimento","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5170-517X","authenticated-orcid":false,"given":"Roberta","family":"Paolillo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6058-4912","authenticated-orcid":false,"given":"Alessandra","family":"Spinelli","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6096-2768","authenticated-orcid":false,"given":"Stefano","family":"Cristiano","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6897-9807","authenticated-orcid":false,"given":"Fiorenzo","family":"Simonetti","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Semplice","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"D\u2019Alconzo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato Maria","family":"Vallone","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-1687","authenticated-orcid":false,"given":"Giuseppe","family":"Giugliano","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7964-4479","authenticated-orcid":false,"given":"Alessandro","family":"Sciahbasi","sequence":"additional","affiliation":[{"name":"Interventional Cardiology, Sandro Pertini Hospital, 00157 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-4952","authenticated-orcid":false,"given":"Plinio","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6943-278X","authenticated-orcid":false,"given":"Felice","family":"Gragnano","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"},{"name":"Division of Cardiology, Azienda Ospedaliera di Rilievo Nazionale Sant\u2019Anna e San Sebastiano, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-830X","authenticated-orcid":false,"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"},{"name":"Division of Cardiology, Azienda Ospedaliera di Rilievo Nazionale Sant\u2019Anna e San Sebastiano, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4395-6742","authenticated-orcid":false,"given":"Giuseppe","family":"Gargiulo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: Update From the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCINTERVENTIONS.113.001150","article-title":"Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions","volume":"7","author":"Capodanno","year":"2014","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4244\/EIJ-D-17-00468","article-title":"State of the art: Duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation\u2014Past, present and future perspectives","volume":"13","author":"Gargiulo","year":"2017","journal-title":"EuroIntervention"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulation Undergoing Percutaneous Coronary Intervention","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"ref_7","first-page":"527","article-title":"Antiplatelet Therapy in Patients Requiring Oral Anticoagulation and Undergoing Percutaneous Coronary Intervention","volume":"13","author":"Manzi","year":"2024","journal-title":"Interv. Cardiol. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gragnano, F., Capolongo, A., Micari, A., Costa, F., Garcia-Ruiz, V., De Sio, V., Terracciano, F., Cesaro, A., Moscarella, E., and Coletta, S. (2023). Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010098"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/FJC.0000000000001607","article-title":"Management of Patients Treated with Oral Anticoagulant Therapy Undergoing Percutaneous Coronary Intervention with Stent Implantation: The PERSEO Registry","volume":"84","author":"Sciahbasi","year":"2024","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1055\/s-0041-1726298","article-title":"Single, Dual, and Triple Antithrombotic Therapy in Cancer Patients with Coronary Artery Disease: Searching for Evidence and Personalized Approaches","volume":"47","author":"Santoro","year":"2021","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4244\/EIJ-D-20-01197","article-title":"Mortality after bleeding versus myocardial infarction in coronary artery disease: A systematic review and meta-analysis","volume":"17","author":"Piccolo","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.05.085","article-title":"Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: Do Bleeding and Stent Thrombosis Weigh Similar on Mortality?","volume":"66","author":"Capodanno","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacc.2020.11.046","article-title":"Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized with Acute Coronary Syndromes","volume":"77","author":"Leonardi","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jcin.2024.08.022","article-title":"Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions","volume":"17","author":"Galli","year":"2024","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.jcin.2024.09.011","article-title":"Antithrombotic Therapy in High Bleeding Risk, Part II: Noncardiac Percutaneous Interventions","volume":"17","author":"Galli","year":"2024","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.124.072009","article-title":"Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention","volume":"151","author":"Gragnano","year":"2024","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","article-title":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"f50","DOI":"10.1093\/ehjcvp\/pvaa116","article-title":"Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: A collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"7","author":"Gargiulo","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Gragnano, F., Capolongo, A., Terracciano, F., Gargiulo, G., De Sio, V., Cesaro, A., Moscarella, E., Patti, G., Porto, I., and Esposito, G. (2022). Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice. J. Clin. Med., 11.","DOI":"10.3390\/jcm11216246"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: A systematic review and meta-analysis of randomized clinical trials","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ehjcvp\/pvae054","article-title":"Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: A randomized, crossover trial","volume":"10","author":"Piccolo","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_22","first-page":"e41311","article-title":"Advancements in Percutaneous Coronary Intervention Techniques: A Comprehensive Literature Review of Mixed Studies and Practice Guidelines","volume":"15","author":"Abubakar","year":"2023","journal-title":"Cureus"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamacardio.2024.0133","article-title":"Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis","volume":"9","author":"Valgimigli","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12265-020-09969-4","article-title":"Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: A MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale: The FABOLUS FASTER Trial","volume":"14","author":"Gargiulo","year":"2021","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/CIRCULATIONAHA.123.063946","article-title":"Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials","volume":"148","author":"Bikdeli","year":"2023","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2024.07.045","article-title":"Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results","volume":"84","author":"Stone","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacc.2018.12.023","article-title":"Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients with Acute Coronary Syndrome","volume":"73","author":"Gargiulo","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jacc.2018.01.033","article-title":"Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes","volume":"71","author":"Gargiulo","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jcin.2016.05.038","article-title":"Bivalirudin in Current Practice: Melius Abundare Quam Deficere?","volume":"9","author":"Valgimigli","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/2048872615572599","article-title":"Bivalirudin versus heparin with or without glycoprotein IIb\/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials","volume":"5","author":"Capodanno","year":"2016","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_32","first-page":"E18","article-title":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.jacc.2010.01.039","article-title":"The transradial approach to percutaneous coronary intervention: Historical perspective, current concepts, and future directions","volume":"55","author":"Rao","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4244\/EIJV8I1A12","article-title":"Multicenter Evaluation of Single High-Dose Bolus Tirofiban vs. Abciximab with Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study. Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction","volume":"8","author":"Vranckx","year":"2012","journal-title":"EuroIntervention"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jcin.2011.08.018","article-title":"Transradial versus transfemoral intervention for acute myocardial infarction: A propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell\u2019Emilia-Romagna) multicenter registry","volume":"5","author":"Valgimigli","year":"2012","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(11)60404-2","article-title":"Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): A randomised, parallel group, multicentre trial","volume":"377","author":"Jolly","year":"2011","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/S0140-6736(15)60292-6","article-title":"Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: A randomised multicentre trial","volume":"385","author":"Valgimigli","year":"2015","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.jacc.2017.02.070","article-title":"Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX","volume":"69","author":"Cortese","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/CIRCULATIONAHA.122.061527","article-title":"Effects on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: Meta-Analysis of Individual Patient Data From 7 Multicenter Randomized Clinical Trials","volume":"146","author":"Gargiulo","year":"2022","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e971","DOI":"10.4244\/EIJ-D-21-00441","article-title":"Prediction of radial crossover in acute coronary syndromes: Derivation and validation of the MATRIX score","volume":"17","author":"Gragnano","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.jcin.2019.06.027","article-title":"Femoral Access with or Without Vascular Closure Device or Radial Access in Acute Coronary Syndrome","volume":"12","author":"Gragnano","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4244\/EIJ-D-22-00809","article-title":"Ultrasound guidance for transfemoral access in coronary procedures: An individual participant-level data metaanalysis from the femoral ultrasound trialist collaboration","volume":"20","author":"Alrashidi","year":"2024","journal-title":"EuroIntervention"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4244\/EIJ-E-23-00051","article-title":"Should we routinely use ultrasound-guided transfemoral access for coronary procedures? High-quality evidence from an individual participant data meta-analysis","volume":"20","author":"Gargiulo","year":"2024","journal-title":"EuroIntervention"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14779072.2021.1902806","article-title":"Differences in coronary artery disease and outcomes of percutaneous coronary intervention with drug-eluting stents in women and men","volume":"19","author":"Greco","year":"2021","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2021.11.028","article-title":"Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes","volume":"15","author":"Laudani","year":"2022","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk","volume":"373","author":"Urban","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","article-title":"Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial","volume":"9","author":"Ariotti","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijcard.2018.09.120","article-title":"Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates","volume":"277","author":"Gargiulo","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): A randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk","volume":"382","author":"Windecker","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/CIRCULATIONAHA.123.065448","article-title":"Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial","volume":"148","author":"Valgimigli","year":"2023","journal-title":"Circulation"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jcin.2009.10.033","article-title":"The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation","volume":"3","author":"Suh","year":"2010","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e004795","DOI":"10.1161\/CIRCINTERVENTIONS.116.004795","article-title":"Impact of Stent Size Selection on Acute and Long-Term Outcomes After Drug-Eluting Stent Implantation in De Novo Coronary Lesions","volume":"10","author":"Kitahara","year":"2017","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijcard.2019.03.034","article-title":"Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration","volume":"287","author":"Camaj","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1093\/eurheartj\/ehy285","article-title":"Clinical use of intracoronary imaging. Part 1: Guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions","volume":"39","author":"Mintz","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/eurheartjsupp\/suae004","article-title":"Intracoronary imaging to guide percutaneous coronary intervention: From evidence to guidelines","volume":"26","author":"Gatto","year":"2024","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/eurheartj\/ehi882","article-title":"Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation","volume":"27","author":"Hong","year":"2006","journal-title":"Eur. Heart J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e036065","DOI":"10.1161\/JAHA.124.036065","article-title":"Stent Underexpansion Is an Underestimated Cause of Intrastent Restenosis: Insights From RESTO Registry","volume":"13","author":"Souteyrand","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jcin.2019.09.033","article-title":"Effect of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation: 5-Year Follow-Up of the IVUS-XPL Randomized Trial","volume":"13","author":"Hong","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcin.2020.10.001","article-title":"3-Year Outcomes of the ULTIMATE Trial Comparing Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation","volume":"14","author":"Gao","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa2307770","article-title":"OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions","volume":"389","author":"Holm","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMoa2305861","article-title":"Optical Coherence Tomography-Guided versus Angiography-Guided PCI","volume":"389","author":"Ali","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1056\/NEJMoa2216607","article-title":"Intravascular Imaging-Guided or Angiography-Guided Complex PCI","volume":"388","author":"Lee","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(23)02454-6","article-title":"Intravascular imaging-guided coronary drug-eluting stent implantation: An updated network meta-analysis","volume":"403","author":"Stone","year":"2024","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1161\/CIRCULATIONAHA.123.067583","article-title":"Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis","volume":"149","author":"Giacoppo","year":"2024","journal-title":"Circulation"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.4244\/EIJ-D-24-00755","article-title":"Outcomes of intravascular imaging-guided percutaneous coronary intervention according to lesion complexity","volume":"21","author":"Lee","year":"2025","journal-title":"EuroIntervention"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): A randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge","year":"2024","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4244\/EIJ-D-20-00052","article-title":"Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores","volume":"16","author":"Ueki","year":"2020","journal-title":"EuroIntervention"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1093\/eurheartj\/ehaa671","article-title":"Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk","volume":"41","author":"Corpataux","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.4244\/EIJV16I14A202","article-title":"Consolidating the value of the standardised ARC-HBR definition","volume":"16","author":"Gargiulo","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e021965","DOI":"10.1161\/JAHA.121.021965","article-title":"Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria","volume":"10","author":"Spirito","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.4244\/EIJ-D-21-00181","article-title":"Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition","volume":"17","author":"Gragnano","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.4244\/EIJ-D-24-00100","article-title":"Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: Rationale and design of the WOEST-3 randomised trial","volume":"20","author":"Verburg","year":"2024","journal-title":"EuroIntervention"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/CIRCULATIONAHA.123.065614","article-title":"Associations of Apixaban Dose with Safety and Effectiveness Outcomes in Patients with Atrial Fibrillation and Severe Chronic Kidney Disease","volume":"148","author":"Xu","year":"2023","journal-title":"Circulation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e029865","DOI":"10.1161\/JAHA.122.029865","article-title":"Benefits and Harms of Standard Versus Reduced-Dose Direct Oral Anticoagulant Therapy for Older Adults with Multiple Morbidities and Atrial Fibrillation","volume":"12","author":"Hayes","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e656","DOI":"10.4244\/EIJ-D-21-01044","article-title":"Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: Primary results from the AVIATOR 2 international registry","volume":"18","author":"Chandrasekhar","year":"2022","journal-title":"EuroIntervention"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.4244\/EIJ-D-21-00703","article-title":"Dual versus triple antithrombotic therapy after percutaneous coronary intervention: The prospective multicentre WOEST 2 Study","volume":"18","author":"Bor","year":"2022","journal-title":"EuroIntervention"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/ehjcvp\/pvaa088","article-title":"Combinations of antithrombotic therapies prescribed after percutaneous coronary intervention in patients with acute coronary syndromes and atrial fibrillation: Data from the nationwide MATADOR-PCI registry","volume":"7","author":"Bolognese","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"474","DOI":"10.4244\/EIJ-D-20-00799","article-title":"Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: A post hoc analysis of the randomised RE-DUAL PCI trial","volume":"17","author":"Zeymer","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1093\/eurheartj\/ehaa617","article-title":"Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: A pre-specified analysis of the ENTRUST-AF PCI trial","volume":"41","author":"Vranckx","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/CIRCULATIONAHA.119.044584","article-title":"Stent Thrombosis in Patients with Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial","volume":"141","author":"Lopes","year":"2020","journal-title":"Circulation"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.120.046534","article-title":"Risk\/Benefit Tradeoff of Antithrombotic Therapy in Patients with Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS","volume":"141","author":"Alexander","year":"2020","journal-title":"Circulation"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jcin.2017.11.009","article-title":"Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial","volume":"11","author":"Kerneis","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","article-title":"Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: A subgroup analysis from the RE-DUAL PCI trial","volume":"40","author":"Oldgren","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1161\/CIRCULATIONAHA.119.043308","article-title":"Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial","volume":"140","author":"Windecker","year":"2019","journal-title":"Circulation"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"Open-Label Randomized Trial Comparing Oral Anticoagulation with and Without Single Antiplatelet Therapy in Patients with Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation","volume":"139","author":"Shizuta","year":"2019","journal-title":"Circulation"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5905022","DOI":"10.1155\/2022\/5905022","article-title":"Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease","volume":"2022","author":"Fukamachi","year":"2022","journal-title":"J. Interv. Cardiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2024.12.030","article-title":"Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials","volume":"85","author":"Rashedi","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_104","first-page":"1","article-title":"Single vs dual antithrombotic therapy in patients with OAC and stabilised CAD: Meta-analysis of randomised trials","volume":"26","author":"Gargiulo","year":"2025","journal-title":"J. Cardiovasc. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.121.056680","article-title":"Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk with or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial","volume":"144","author":"Smits","year":"2021","journal-title":"Circulation"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2020.05.024","article-title":"Commentary: Temporarily omitting oral anticoagulants early after stenting for acute coronary syndromes patients with atrial fibrillation","volume":"318","author":"Limbruno","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or with Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/CIRCULATIONAHA.124.070797","article-title":"Swinging Pendulum Between Risks and Benefits of Antiplatelet Agents: A Call for Consistency in the Interpretation of Evidence and Guideline Recommendations","volume":"151","author":"Landi","year":"2025","journal-title":"Circulation"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Canonico, M.E., Sanna, G.D., Siciliano, R., Scudiero, F., Esposito, G., and Parodi, G. (2022). Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.916361"}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/12\/4\/142\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:12:33Z","timestamp":1760029953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/12\/4\/142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":110,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcdd12040142"],"URL":"https:\/\/doi.org\/10.3390\/jcdd12040142","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]}}}